The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia

• Type of Material: Article
• Authors: Michael M. Boyiadzis, University of Pittsburgh; Ivan Aksentijevich, Virginia Canc Specialists; Daniel A. Arber, University of Chicago; John Barrett, National Heart, Lung, and Blood Institute; Renier J. Brentjens, Memorial Sloan Kettering Cancer Center; Jill Brufsky, University of Pittsburgh; Jorge Cortes, Georgia Cancer Center; Marcos De Lima, University Hospitals of Cleveland; Stephen J. Forman, City of Hope National Medical Center; Ephraim J. Fuchs, Johns Hopkins University; Linda J. Fukas, University of Pittsburgh; Steven D. Gore, National Cancer Institute; Mark R. Litzow, Mayo Clinic; Jeffrey S. Miller, University of Minnesota; John M. Pagel, Swedish Cancer Institute; Edmund Waller, Emory University; Martin S. Tallman, Memorial Sloan Kettering Cancer Center
• Language: English
• Date: 2020-01-01
• Publisher: BMJ PUBLISHING GROUP
• Publication Version: Final Published Version
• Copyright Statement: © Author(s) (or their employer(s)) 2020.
• License: Creative Commons Attribution-NonCommercial 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1136/jitc-2020-000810
• Title of Journal or Parent Work: JOURNAL FOR IMMUNOTHERAPY OF CANCER
• Volume: 8
• Issue: 2
• Grant/Funding Information: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
• Keywords: STEM-CELL TRANSPLANTATION; hematological neoplasms; chimeric antigen; ACUTE LYMPHOBLASTIC-LEUKEMIA; Science & Technology; INOTUZUMAB OZOGAMICIN; guidelines as topic; Immunology; CYTOKINE RELEASE SYNDROME; ACUTE MYELOID-LEUKEMIA; ADULT PATIENTS; MINIMAL RESIDUAL DISEASE; DONOR LYMPHOCYTE INFUSIONS; GEMTUZUMAB OZOGAMICIN; immunotherapy; antineoplastic protocols; Life Sciences & Biomedicine; SINGLE-ARM; receptors; Oncology
• Research Categories: Health Sciences, Immunology; Health Sciences, Oncology; Biology, Cell; Health Sciences, Medicine and Surgery

Abstract

Acute leukemia is a constellation of rapidly progressing diseases that affect a wide range of patients regardless of age or gender. Traditional treatment options for patients with acute leukemia include chemotherapy and hematopoietic cell transplantation. The advent of cancer immunotherapy has had a significant impact on acute leukemia treatment. Novel immunotherapeutic agents including antibody-drug conjugates, bispecific T cell engagers, and chimeric antigen receptor T cell therapies have efficacy and have recently been approved by the US Food and Drug Administration (FDA) for the treatment of patients with acute leukemia. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to develop a clinical practice guideline composed of consensus recommendations on immunotherapy for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia.